soul trial oral semaglutide cardiovascular outcomes results 2024 2025 nejm π§Ώ is the first oral GLP-1 RA proven to reduce MACE in high-risk T2DM patients, extending protection beyond injectable formulations. Trial: Oral Semaglutide & Cardiovascular in T2DM Canadian Perspectives 2025 Whiteboard on
Description
Diabetes Obes Metab 23(Suppl 3):529
Once in circulation, GLP-1 exerts powerful metabolic effects: it enhances glucose-dependent insulin secretion from the pancreas, suppresses excess glucagon, and signals the hypothalamic nuclei in the brain to promote satiety
When Eli Lilly gets FDA approval (expected 2027-2028), retatrutide will be available at retail pharmacies with a standard prescription
What side effects should I know about before using Wellbutrin XL
